Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Phathom Pharmaceuticals Inc

PHAT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$9.58

▲ +4.36%

Market Cap $775.03M · Vol 304.27K

Key Metrics

P/E Ratio

N/A

FWD: 62.92

Market Cap

$775.03M

Small Cap

Div Yield

N/A

EPS Growth

+74.30%

YoY

RSI (14)

29.03

Momentum

Beta

0.52

vs Market

52W High

$18.29

47.62% below

52W Low

$8.21

16.69% above

Volume

304.27K

Avg 460.77K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

78.14%

Public shares

Shariah Compliance8 STANDARDS

✗ Phathom Pharmaceuticals Inc (PHAT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PHAT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.05%

-13.19%

-26.59%

-20.30%

YTD

-42.25%

-8.50%

-37.93%

-70.06%

Financials & Valuation

TTM · Annual

Total Revenue	$175.11M
Net Income	$-221,247,000.00
Revenue Growth (YoY)	+88.02%
Gross Margin	87.09%
Operating Margin	-86.11%
Net Profit Margin	-126.35%
ROE	N/A
ROA · ROIC	-69.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	62.92
PEG Ratio	N/A
P/S	6.91
P/B	N/A
P/FCF	N/A
EPS Growth	+74.30%
Outstanding Shares	80.90M

Technical Indicators

50-Day SMA	$10.44
200-Day SMA	$12.43
RSI (14)	29.03
Beta	0.52
52-Week High	$18.29
52-Week Low	$8.21

Volume Today	304.27K
Avg Daily Volume (30D)	460.77K
Relative Volume	0.66x
Volatility (10D)	55.75
Volatility (30D)	96.04
Free Float	78.14%

Analyst Consensus

BUY

Current Price $9.58

Mean Target $21.50

52W Low$8.21 52W High$18.29

Current

Target

$8.21 $18.29

Current Analyst target

+124.43% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00P5B2S73

ISINUS71722W1071

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.